Regenerative Medicines for Remyelination: From Aspiration to Reality.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26046755.
- Also identified by DOI 10.1016/j.stem.2015.05.010.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Stimulating an endogenous regenerative response is a powerful approach for potential treatment of chronic demyelinating diseases such as multiple sclerosis. Recently in Nature, Najm et al. (2015) identified two clinically relevant, FDA-approved compounds that promote oligodendrocyte progenitor cell differentiation and induce remyelination in demyelinating disease models.
Medical subject headings
- Clobetasol
- Miconazole
- Multiple Sclerosis
- Myelin Sheath
- Pluripotent Stem Cells